Table 2. Summary of rFVIIIFc EDs by... | American Society of Hematology

Table 2.

Summary of rFVIIIFc EDs by treatment regimen in the safety analysis set

	Treatment regimen
	OD (n = 81)	Prophylaxis (n = 89)
Patients with ED milestones, n (%)*,†
≥5	31 (38.3)	84 (94.4)
≥10	8 (9.9)	78 (87.6)
≥20	1 (1.2)	76 (85.4)
≥50	0 (0.0)	64 (71.9)
≥75	0 (0.0)	51 (57.3)
≥100	0 (0.0)	24 (27.0)
EDs, median (range)	4 (0-27)	91 (1-192)

	Treatment regimen
	OD (n = 81)	Prophylaxis (n = 89)
Patients with ED milestones, n (%)*,†
≥5	31 (38.3)	84 (94.4)
≥10	8 (9.9)	78 (87.6)
≥20	1 (1.2)	76 (85.4)
≥50	0 (0.0)	64 (71.9)
≥75	0 (0.0)	51 (57.3)
≥100	0 (0.0)	24 (27.0)
EDs, median (range)	4 (0-27)	91 (1-192)

Safety analysis set (n = 103). Subjects may appear in >1 treatment regimen.

An ED is a 24-h period in which ≥1 rFVIIIFc infusion is given. All infusions across the study are counted.

Refers to EDs within the respective treatment regimen.